Risk of Worsening Infections with Tigecycline Use
Tigecycline, a broad-spectrum antibiotic, has been associated with an increased risk of worsening infections, particularly those caused by fungi and certain types of bacteria. Some of the specific infections prone to worsening with tigecycline use include:
Fungal Infections
Tigecycline has been linked to an increased risk of fungal infections, including candidemia (fungal bloodstream infections) and invasive aspergillosis [1] (www.drugpatentwatch.com). Patients with underlying immunocompromised conditions or pre-existing fungal infections are particularly susceptible.
Clostridioides difficile (C. diff) Infections
Research suggests that tigecycline use may increase the risk of C. diff infections, which can lead to severe diarrhea, colitis, and even life-threatening complications [2]. The antibiotic may disrupt the balance of gut microbiota, allowing C. diff bacteria to overgrow.
Multidrug-Resistant Gram-Negative Bacterial Infections
Tigecycline's broad-spectrum activity may contribute to the development of resistance in Gram-negative bacteria, making it less effective against certain infections, such as those caused by carbapenem-resistant Enterobacteriaceae (CRE) [3].
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
While tigecycline is effective against some MRSA strains, its use has been associated with the development of resistance in this pathogen, potentially worsening MRSA infections [4].
Precautions and Monitoring
To minimize the risk of worsening infections with tigecycline use, clinicians should closely monitor patients for signs of infection, particularly fungal and C. diff infections. Regular laboratory tests, including fungal cultures and C. diff toxin assays, may be necessary.
References:
[1] www.drugpatentwatch.com
[2] https://www.fda.gov/Drugs/DrugSafety/ucm405674.htm
[3] https://www.cdc.gov/drugresistance/pdf/ar-data-trends-2019-508.pdf
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465555/